Bulk Manufacturer of Controlled Substances Application: American Radiolabeled Chemicals, 23070-23071 [2017-10240]
Download as PDF
<![CDATA[
23070
Federal Register / Vol. 82, No. 96 / Friday, May 19, 2017 / Notices
therefore, may file written comments on
or objections to the issuance of the
proposed registration in accordance
with 21 CFR 1301.34(a) on or before
June 19, 2017. Such persons may also
file a written request for a hearing on
the application pursuant to 21 CFR
1301.43 on or before June 19, 2017.
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
ADDRESSES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix of subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on
November 10, 2016, Galephar
Pharmaceutical Research, Inc., #100
Carr 198, Industrial Park, Juncos, Puerto
Rico 00777–3873 applied to be
registered as an importer of
hydromorphone (9150), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance in finished
dosage form for clinical trials, research
and analytical purposes.
The import of this class of controlled
substance will be granted only for
analytical testing, research, and clinical
trials. This authorization does not
extend to the import of a finished FDA
approved or non-approved dosage form
for commercial sale.
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
19:15 May 18, 2017
Jkt 241001
Dated: May 15, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017–10234 Filed 5–18–17; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Whatever LLC
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic class, and applicants
therefore, may file written comments on
or objections to the issuance of the
proposed registration in accordance
with 21 CFR 1301.34(a) on or before
June 19, 2017. Such persons may also
file a written request for a hearing on
the application pursuant to 21 CFR
1301.43 on or before June 19, 2017.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
Comments and requests for hearing on
applications to import narcotic raw
material are not appropriate. 72 FR 3417
(January 25, 2007).
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
DATES:
PO 00000
Frm 00118
Fmt 4703
Sfmt 4703
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on October
16, 2015, Whatever LLC, 4370 N.
Randall Street, Flagstaff, Arizona 86004
applied to be registered as an importer
of opium poppy (9650), a basic class of
controlled substance listed in schedule
II.
The company plans to import opium
poppy (9650), for dried floral decorative
arrangements. Approval of permit
application will occur only when the
registrant’s business activity is
consistent with what is authorized
under to 21 U.S.C. 952(a)(2).
Dated: May 15, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017–10243 Filed 5–18–17; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: American
Radiolabeled Chemicals
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.33(a) on
or before July 18, 2017.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
DATES:
E:\FR\FM\19MYN1.SGM
19MYN1
23071
Federal Register / Vol. 82, No. 96 / Friday, May 19, 2017 / Notices
In accordance with 21 CFR
1301.33(a), this is notice that on March
7, 2017, American Radiolabeled
Chemicals, Inc., 101 Arc Drive, Saint
Louis, Missouri 63146 applied to be
registered as a bulk manufacturer of the
following basic classes of controlled
substances:
Controlled substance
Drug code
Gamma Hydroxybutyric Acid ...........................................................................................................................................
Ibogaine ...........................................................................................................................................................................
Lysergic acid diethylamide ..............................................................................................................................................
Tetrahydrocannabinols ....................................................................................................................................................
Dimethyltryptamine ..........................................................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine ...............................................................................................................................
Dihydromorphine .............................................................................................................................................................
Heroin ..............................................................................................................................................................................
Normorphine ....................................................................................................................................................................
Amphetamine ...................................................................................................................................................................
Methamphetamine ...........................................................................................................................................................
Amobarbital ......................................................................................................................................................................
Phencyclidine ...................................................................................................................................................................
Phenylacetone .................................................................................................................................................................
Cocaine ............................................................................................................................................................................
Codeine ...........................................................................................................................................................................
Dihydrocodeine ................................................................................................................................................................
Oxycodone .......................................................................................................................................................................
Hydromorphone ...............................................................................................................................................................
Ecgonine ..........................................................................................................................................................................
Hydrocodone ...................................................................................................................................................................
Meperidine .......................................................................................................................................................................
Metazocine ......................................................................................................................................................................
Methadone .......................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) ..............................................................................................................
Morphine ..........................................................................................................................................................................
Oripavine .........................................................................................................................................................................
Thebaine ..........................................................................................................................................................................
Oxymorphone ..................................................................................................................................................................
Phenazocine ....................................................................................................................................................................
Carfentanil .......................................................................................................................................................................
Fentanyl ...........................................................................................................................................................................
The company plans to manufacture
small quantities of the listed controlled
substances as radiolabeled compounds
for biochemical research.
Dated: May 15, 2017.
Louis J. Milione,
Assistant Administrator.
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Mallinckrodt LLC
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.34(a) on
DATES:
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
Comments and requests for hearing on
applications to import narcotic raw
material are not appropriate. 72 FR 3417
(January 25, 2007).
ADDRESSES:
[FR Doc. 2017–10240 Filed 5–18–17; 8:45 am]
ACTION:
or before June 19, 2017. Such persons
may also file a written request for a
hearing on the application pursuant to
21 CFR 1301.43 on or before June 19,
2017.
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispenses,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on
December 21, 2016, Mallinckrodt LLC,
3600 North Second Street, Saint Louis,
Missouri 63147 applied to be registered
as an importer of the following basic
classes of controlled substances:
Drug code
Marihuana ........................................................................................................................................................................
19:15 May 18, 2017
Jkt 241001
PO 00000
Frm 00119
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
SUPPLEMENTARY INFORMATION:
Controlled substance
VerDate Sep<11>2014
2010
7260
7315
7370
7435
7470
9145
9200
9313
1100
1105
2125
7471
8501
9041
9050
9120
9143
9150
9180
9193
9230
9240
9250
9273
9300
9330
9333
9652
9715
9743
9801
Schedule
E:\FR\FM\19MYN1.SGM
19MYN1
7360
Schedule
I
]]>Agencies
[Federal Register Volume 82, Number 96 (Friday, May 19, 2017)]
[Notices]
[Pages 23070-23071]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-10240]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: American
Radiolabeled Chemicals
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.33(a) on or before July 18, 2017.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
[[Page 23071]]
In accordance with 21 CFR 1301.33(a), this is notice that on March
7, 2017, American Radiolabeled Chemicals, Inc., 101 Arc Drive, Saint
Louis, Missouri 63146 applied to be registered as a bulk manufacturer
of the following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid.......... 2010 I
Ibogaine........................... 7260 I
Lysergic acid diethylamide......... 7315 I
Tetrahydrocannabinols.............. 7370 I
Dimethyltryptamine................. 7435 I
1-[1-(2- 7470 I
Thienyl)cyclohexyl]piperidine.
Dihydromorphine.................... 9145 I
Heroin............................. 9200 I
Normorphine........................ 9313 I
Amphetamine........................ 1100 II
Methamphetamine.................... 1105 II
Amobarbital........................ 2125 II
Phencyclidine...................... 7471 II
Phenylacetone...................... 8501 II
Cocaine............................ 9041 II
Codeine............................ 9050 II
Dihydrocodeine..................... 9120 II
Oxycodone.......................... 9143 II
Hydromorphone...................... 9150 II
Ecgonine........................... 9180 II
Hydrocodone........................ 9193 II
Meperidine......................... 9230 II
Metazocine......................... 9240 II
Methadone.......................... 9250 II
Dextropropoxyphene, bulk (non- 9273 II
dosage forms).
Morphine........................... 9300 II
Oripavine.......................... 9330 II
Thebaine........................... 9333 II
Oxymorphone........................ 9652 II
Phenazocine........................ 9715 II
Carfentanil........................ 9743 II
Fentanyl........................... 9801 II
------------------------------------------------------------------------
The company plans to manufacture small quantities of the listed
controlled substances as radiolabeled compounds for biochemical
research.
Dated: May 15, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017-10240 Filed 5-18-17; 8:45 am]
BILLING CODE P
